Synthesis and Evaluation of [DUPA-6-Ahx-Lys (DOTA)-6-Ahx-RM2], a Novel, Bivalent Targeting Ligand for GRPr/PSMA Biomarkers of Prostate Cancer

Authors

  • Rajendra Prasad Bandari University of Missouri
  • Michael Robert Lewis University of Missouri
  • Charles Jeffrey Smith University of Missouri

Keywords:

Gastrin-releasing peptide receptor, prostate cancer, bombesin, antagonist, Chelating agent

Abstract

In this study, we have prepared a novel, dual-biomarker, targeting ligand having high affinity and specificity for PSMA/GRPr receptors that are expressed on most prostate cancers.  [DUPA-6-Ahx-Lys(DOTA)-6-Ahx-RM2] was synthesized and the new conjugate was metallated macroscopically with GaCl3, InCl3, and LuCl3 to form [DUPA-6-Ahx-Lys(M-DOTA)-6-Ahx-RM2] (where M = Ga, In, or Lu).  These new agents, when radiolabeled with Ga-68, In-111, or Lu-177 hold theranostic potential for patients presenting with prostate cancer disease.

Author Biography

Charles Jeffrey Smith, University of Missouri

Department of Radiology
University of Missouri Columbia, 65211

DUPA DOTA radiopharmaceutical

Published

2018-01-31

How to Cite

Bandari, R. P., Lewis, M. R., & Smith, C. J. (2018). Synthesis and Evaluation of [DUPA-6-Ahx-Lys (DOTA)-6-Ahx-RM2], a Novel, Bivalent Targeting Ligand for GRPr/PSMA Biomarkers of Prostate Cancer. Chemical Biology Letters, 5(1), 11-24. Retrieved from http://thesciencein.org/journal/index.php/cbl/article/view/39

Issue

Section

Research Articles